Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score...

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Background:

• Refractory bleeding is a significant complication in acute aortic dissection surgery.
• Deep hypothermic circulatory arrest (DHCA) increases surgical complexity and bleeding risk.
• Conventional methods may be insufficient for managing severe hemorrhage in these patients.

Purpose of the Study:

• To evaluate the safety and effectiveness of recombinant activated factor VII (rFVIIa) as an adjunct therapy.
• To assess rFVIIa's impact on blood loss and transfusion requirements.
• To determine the incidence of adverse events associated with rFVIIa use in this specific patient population.

Main Methods:

• A propensity score-matched analysis was conducted.
• Twenty-three cardiac surgery patients receiving rFVIIa were compared to 23 matched controls.
• rFVIIa was administered as an intravenous bolus (70 microg/kg) post-transfusion protocol.

Main Results:

• rFVIIa administration significantly reduced blood loss and transfusion requirements.
• Hourly blood loss showed significant decreases post-rFVIIa administration (p < .001).
• Significant improvements were observed in coagulation parameters (INR, PTT, platelet count, fibrinogen, antithrombin) with no difference in adverse events between groups.

Conclusions:

• rFVIIa demonstrated successful use as an additional therapy for refractory bleeding during and after acute aortic dissection surgery with DHCA.
• rFVIIa can be a valuable option when conventional hemostatic methods are inadequate.
• Randomized studies are warranted to definitively confirm the safety and efficacy of rFVIIa in this context.